Multiple sclerosis (MS) is a debilitating autoimmune disorder. Currently, there is a lack of
effective treatment for the progressive form of MS, partly due to insensitive readout for …

Biomarkers can be thought of as multifaceted indicators of healthy status or of pathological
disorders. The study of multiple sclerosis can benefit from the use of biomarkers because of …

Diagnosis of multiple sclerosis (MS) requires the exclusion of other possible diagnoses. For
this reason, the cerebrospinal fluid (CSF) should be routinely analysed in patients with a first …

Multiple sclerosis (MS) is a neurodegenerative disease associated with inflammatory
demyelination and astroglial activation, with neuronal and axonal damage as the leading …

Objective: Axonal degeneration is the likely cause of disease progression in multiple
sclerosis (MS). Our previous results indicated that neuron-specific N-acetylaspartate (NAA) …

Objective To test the hypothesis that the pattern of serum biomarkers of disease activity and
disability in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) will …

Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that
predominantly affects white matter. MS has a variable clinical presentation and has no …

Nowadays, there is a need for reliable fluid biomarkers to improve differential diagnosis,
prognosis, and the prediction of treatment response, particularly in the management of …

Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) in which
the complex interplay between inflammation and neurodegeneration determines varying …

Introduction Multiple sclerosis (MS) is the most frequent demyelinating disease of the central
nervous system. Although there is currently there is no definite cure for MS, new therapies …